Skip to main content
MLYS logo

MLYS · Mineralys Therapeutics, Inc. · Investor Relations

Track MLYS — free
$14.51 -0.02 (-0.14%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.29B
Shares
88.56M
Volume · Nov 17 364.79K Avg daily vol (3M) 1.52M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-12-01 18:45 UTC 9th Annual Evercore Healthcare Conference Conference

Recent news

Date Headline
2026-11-08 Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
2026-11-06 Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-03 Mineralys Therapeutics to Participate in Upcoming Investor Conferences
2026-10-28 Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
2026-10-28 Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
2026-10-22 Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
2026-10-19 Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
2026-10-09 Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
2026-10-02 Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
2026-08-11 Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-06-03 Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
2026-05-06 Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-03-12 Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
2026-03-09 Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
2026-01-06 Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
2025-11-10 Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Past events

Source: https://ir.mineralystx.com/

Key facts CIK 1933414 CUSIP 603170101 13F (30d) 218 filings 206 filers Visit website Investor relations